NDATOPICALGEL, METERED
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOFDRA (sofpironium bromide) is a topical metered gel approved by the FDA in June 2024 for an indication in dermatology. The mechanism of action and specific indication are not disclosed in available regulatory data. This represents a novel topical formulation from Botanix Pharmaceuticals entering the market in early growth phase.
Growth13.9 years to LOE
Recent 2024 approval positions SOFDRA in early commercial expansion; team size and investment trajectory depend on market uptake and reimbursement success.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Started Dec 2020
351 enrolled
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Started Oct 2020
350 enrolled
Axillary Hyperhidrosis
Career Relevance
SOFDRA represents a newly launched topical product with no established market presence or linked jobs yet, creating opportunity for early-career professionals to build the commercial infrastructure from the ground up. Working on this product offers visibility, autonomy, and the chance to shape market positioning during critical growth phase.
Worked on SOFDRA at Botanix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.